Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease
Authors:
Open Access
- 2 July 2021
- journal article
- research article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 478 (13) , 2445-2464
Abstract
SARS-CoV-2 is a coronavirus that emerged in 2019 and rapidly spread across the world causing a deadly pandemic with tremendous social and economic costs. Healthcare systems worldwide are under great pressure, and there is an urgent need for effective antiviral treatments. The only currently approved antiviral treatment for COVID-19 is remdesivir, an inhibitor of viral genome replication. SARS-CoV-2 proliferation relies on the enzymatic activities of the non-structural proteins (nsp), which makes them interesting targets for the development of new antiviral treatments. With the aim to identify novel SARS-CoV-2 antivirals, we have purified the exoribonuclease/methyltransferase (nsp14) and its cofactor (nsp10) and developed biochemical assays compatible with high-throughput approaches to screen for exoribonuclease inhibitors. We have screened a library of over 5000 commercial compounds and identified patulin and aurintricarboxylic acid (ATA) as inhibitors of nsp14 exoribonuclease in vitro. We found that patulin and ATA inhibit replication of SARS-CoV-2 in a VERO E6 cell-culture model. These two new antiviral compounds will be valuable tools for further coronavirus research as well as potentially contributing to new therapeutic opportunities for COVID-19.Keywords
All Related Versions
This publication has 77 references indexed in Scilit:
- Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential TherapeuticsPLOS Pathogens, 2013
- RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complexProceedings of the National Academy of Sciences, 2012
- The Cellular RNA Helicase DDX1 Interacts with Coronavirus Nonstructural Protein 14 and Enhances Viral ReplicationJournal of Virology, 2010
- Infidelity of SARS-CoV Nsp14-Exonuclease Mutant Virus Replication Is Revealed by Complete Genome SequencingPLOS Pathogens, 2010
- In Vitro Reconstitution of SARS-Coronavirus mRNA Cap MethylationPLOS Pathogens, 2010
- Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferaseProceedings of the National Academy of Sciences, 2009
- High Fidelity of Murine Hepatitis Virus Replication Is Decreased in nsp14 Exoribonuclease MutantsJournal of Virology, 2007
- The 1944 patulin trial of the British Medical Research CouncilJournal of the Royal Society of Medicine, 2006
- A detergent-based assay for the detection of promiscuous inhibitorsNature Protocols, 2006
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004